£30m liver cirrhosis study paves the way for new treatments
The most extensive clinical study into liver cirrhosis ever conducted worldwide has been announced by Newcastle University, University of Edinburgh and major research-driven global biopharmaceutical company, Boehringer Ingelheim. The ADVANCE (Accelerating Discovery: Actionable NASH Cirrhosis Endpoints) study will be the most detailed observational study of its kind, enrolling the largest number of patients and providing […]